Long-term safety study of sonelokimab for psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study is for people who have already been in a previous trial of sonelokimab for psoriatic arthritis and want to continue treatment. It checks how safe and effective the medicine is over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous study of sonelokimab for psoriatic arthritis.
- You must have received your last dose of study medicine within the last 8 weeks (ideally 4 weeks) before starting this study.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must agree to use effective birth control for at least 8 weeks after the last dose.
- Men must agree to use a condom during sex with a partner who could become pregnant, and not donate sperm, for at least 8 weeks after the last dose.
- You must not have been unblinded (told which group you were in) during the previous study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called sonelokimab for people with active psoriatic arthritis who have already tried a TNF-alpha inhibitor (like adalimumab) and it didn't work well enough. The goal is to see if sonelokimab can reduce joint pain and swelling and improve skin symptoms.
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
This trial tests the long-term safety and effectiveness of Lunsekimig, an investigational drug, for adults with asthma. It is for people who have already completed a previous Lunsekimig study and are on stable asthma medications.
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
This study is a continuation for people who already took ORKA-001 for plaque psoriasis and did well. It tests whether staying on the medicine keeps helping without any new safety concerns.
Hear when a new Arthritis, Psoriatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.